FDA adds boxed warning to Duchenne gene therapy
The FDA on Nov. 14 added a boxed warning to Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy after two patient deaths and limited its approved use to ambulatory patients age 4 and older. New labeling also recommends weekly liver‑function monitoring for the first three months post‑infusion and other precautions, affecting how Twin Cities providers prescribe and monitor the one‑time treatment.
This story is compiled from 1 source using AI-assisted curation and analysis. Original reporting is attributed below. Learn about our methodology.
📌 Key Facts
- FDA issued a boxed warning for potentially fatal liver failure with Elevidys
- Use narrowed to ambulatory patients aged 4+ (no longer for non‑ambulatory patients)
- Label advises weekly liver tests for three months after infusion
📰 Source Timeline (1)
Follow how coverage of this story developed over time
November 14, 2025